ClinicalTrials.gg
CompletedNCT00141388Updated Nov 6, 2009

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures

A Phase 3 interventional study of Pregabalin in Seizure Disorder, Partial, sponsored by Pfizer. Completed at 56 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-11-06.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
455
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing pregabalin in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Pregabalin · Epilepsies, Partial.

Enrollment
5th of 18
455 · median 244
Started
1998
with 1 other
Phase 3
12 of 18
none open now
Registered
1st of 18
by date
Lead sponsor
7 of 18
Pfizer

Among the 18 studies testing pregabalin in Epilepsies, Partial, this one is the 5th largest by enrollment, is one of 2 that started in 1998, is one of 12 in phase 3, and was the 1st registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing pregabalin in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing pregabalin in Epilepsies, Partial as a file.
02

Study summary

To evaluate the long-term safety and efficacy of pregabalin in patients with partial seizures.

03

Conditions studied

  • Seizure Disorder, Partial

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have met the inclusion criteria for the preceding double-blind study
  • Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion criteria

Exclusion Criteria:

  • Cannot have absence seizures.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
455 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Safety Efficacy

07

Study locations

56 sites
  • Pfizer Investigational Site
    Birmingham, Alabama 35249, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35255, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35294-0021, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85006, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85712-2809, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85712, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pfizer Investigational Site
    Los Angeles, California 90033, United States
  • Pfizer Investigational Site
    Pasadena, California 91105, United States
  • Pfizer Investigational Site
    Gainesville, Florida 32608-1197, United States
  • Pfizer Investigational Site
    Gainesville, Florida 32610, United States
  • Pfizer Investigational Site
    Miami, Florida 33136, United States
  • Pfizer Investigational Site
    Plantation, Florida 33317, United States
  • Pfizer Investigational Site
    Spring Hill, Florida 34609, United States
  • Pfizer Investigational Site
    Tallahassee, Florida 32308, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60612, United States
  • Pfizer Investigational Site
    Springfield, Illinois 62702, United States
  • Pfizer Investigational Site
    Springfield, Illinois 62704, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46202, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46254, United States
  • Pfizer Investigational Site
    Iowa City, Iowa 52242, United States
  • Pfizer Investigational Site
    Kansas City, Kansas 66160-7314, United States
  • Pfizer Investigational Site
    Kansas City, Kansas 66160, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40205, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21201, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21224, United States
  • Pfizer Investigational Site
    Greenbelt, Maryland 20770, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02130, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02215, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48108, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Pfizer Investigational Site
    St. Paul, Minnesota 55102, United States
  • Pfizer Investigational Site
    Chesterfield, Missouri 63017, United States
  • Pfizer Investigational Site
    Columbia, Missouri 65212, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63110-1092, United States
  • Pfizer Investigational Site
    St. Louis, Missouri 63110, United States
  • Pfizer Investigational Site
    Lebanon, New Hampshire 03756, United States
  • Pfizer Investigational Site
    New York, New York 10016, United States
  • Pfizer Investigational Site
    New York, New York 10032, United States
  • Pfizer Investigational Site
    Rochester, New York 14642, United States
  • Pfizer Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44195, United States
  • Pfizer Investigational Site
    Columbus, Ohio 43210, United States
  • Pfizer Investigational Site
    Portland, Oregon 97227, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232, United States
  • Pfizer Investigational Site
    Dallas, Texas 75230, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Bennington, Vermont 05201, United States
  • Pfizer Investigational Site
    Edmonton, Alberta T5H 3V9, Canada
  • Pfizer Investigational Site
    Edmont, Alberta T5G 0B7, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V52 1M9, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V67 1Y6, Canada
  • Pfizer Investigational Site
    London, Ontario N6A 5A5, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M4Y 1J3, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H3A 2B4, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 1998 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 1, 2005
Start
Jul 1998
CompletionActual
Oct 2005
Last update
Nov 6, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00141388
Lead sponsor
Pfizer
First posted
Sep 1, 2005
Start date
Jul 1998
Completion
Oct 2005
Last update
Nov 6, 2009

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion